Incyte
NASDAQ:INCYBiotechWilmington, Delaware, United States · Est. 1991 · 3,200 employees
Incyte is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule and biologic drugs in oncology and inflammation.
20
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
30
Indications↗
Distinct diseases across all programs
296
Clinical Trials↗
All sponsored trials (all statuses)
53
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
20 drugs in development
Phase 38
Phase 210
Phase 14
By Therapeutic Area
top 6
Oncology
1252%
Dermatology
313%
Respiratory
313%
Infectious Disease
29%
Immunology
14%
Hematology
14%
R&D Momentum
73/100
Pipeline Velocity
43/100
Trial Completion Rate
64/100
Pipeline Concentration
32/100
Pipeline Freshness
73/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Approved for marketing
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
Jul 10, 2026
Recruiting
A Phase 3, Randomized, Double-Blind, Safety, and Efficacy Study of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Jul 9, 2026
Recruiting
A Phase 1, Single Dose, Open-Label, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
Jul 9, 2026
Active, not recruiting
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Jul 8, 2026
Active, not recruiting
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Jul 7, 2026
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
Jul 7, 2026
Completed
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
Jul 7, 2026
Recruiting
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Jul 7, 2026
Recruiting
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Jul 7, 2026
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Jul 7, 2026
Recruiting
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Jul 7, 2026
Recruiting
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Details
Company Info
Company Overview
$16.0B
Mkt Cap
$3.5B
Revenue
—
Cash
CEOHervé Hoppenot
Founded1991
Employees3,200
HQWilmington, Delaware, United States
ExchangeNASDAQ:INCY
Websiteincyte.com
LinkedInCompany Page
Therapeutic Focus
HematologyImmunologyOncologyInfectious DiseaseOtherDermatologyCardiovascularRare DiseaseNeurologyRespiratoryGastroenterologyNephrologyMetabolic & Endocrine
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Dermatology(3 drugs)
—
—
1
3
—
Dermatology(3 drugs)
Hematology(1 drug)
—
—
1
—
—
Hematology(1 drug)
Immunology(1 drug)
—
—
—
1
—
Immunology(1 drug)
Infectious Disease(2 drugs)
—
—
1
1
—
Infectious Disease(2 drugs)
Oncology(12 drugs)
—
4
6
3
—
Oncology(12 drugs)
Respiratory(3 drugs)
—
—
3
—
—
Respiratory(3 drugs)
Unknown / Other(1 drug)
—
—
1
—
—
Unknown / Other(1 drug)
Regulatory
Regulatory Timeline
20111 event
FDANov 16
Jakafi — JAKAFI
Application NDA202192 (NDA)
20201 event
FDAApr 17
Pemazyre — PEMAZYRE
Application NDA213736 (NDA)
20211 event
FDASep 21
Jakafi — OPZELURA
Application NDA215309 (NDA)
20261 event
FDAMay 1
Jakafi — JAKAFI XR
Application NDA217180 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)